Premium
Disopyramide analysis using REMEDi: Comparison with EMIT and conventional high performance liquid chromatographic methods
Author(s) -
Patel V.,
McCarthy P. T.,
Flanagan R. J.
Publication year - 1991
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.1130050609
Subject(s) - disopyramide , chromatography , chemistry , high performance liquid chromatography , metabolite , extraction (chemistry) , urine , solvent , medicine , biochemistry , organic chemistry , cardiology
REMEDi ( Rapid EME rgency D rug i dentification; Bio‐Rad) is an automated high performance liquid chromatographic (HPLC) system designed to detect, identify and measure a range of basic and neutral drugs in 0.5‐1.0 mL of urine or plasm/serum. We have evaluated REMEDi in the analysis of the antiarrhythmic drug disopyramide in patient samples. The specimens were also analysed by a conventional HPLC method, based on solvent extraction and UV detection (254 nm), and by EMIT. There were good correlations between the results obtained with each method ( r = 0.91 or greater). REMEDi gave a lower mean result than EMIT [means±SD (m/L): REMEDi 2.64±1.10, EMIT 3.14±1.51; t = 4.0, p <0.01; n = 25], but there were no other significant differences in mean results. The principal disopyramide metabolite, mono‐ N ‐desalkyldisopyramide, did not interfere in any method. Clearly REMEDi can be used for therapeutic drug monitoring of disopyramide provided enough sample is available.